Another small molecule, CT1812 (ElaytaTM), an antagonist of σ2-R, is being tested for the treatment of Alzheimer’s disease in Phase 2 clinical trials [146,147]. Here, TMEM97 is linked to early-onset autosomal dominant Alzheimer disease.